Malignant tumor after renal transplantation

Japanese Journal of Nephrology

Volumn 47, Issue 4, 2005, Pages 430-436

  Sugitani, Atsushi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZACITIDINE; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; DNA; HLA B27 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PROTEIN P53; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; VALACICLOVIR; VASCULOTROPIN;

APOPTOSIS; BURKITT LYMPHOMA; EPSTEIN BARR VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; KAPOSI SARCOMA; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; KIDNEY TUMOR; LYMPHOPROLIFERATIVE DISEASE; POLYMERASE CHAIN REACTION; REGISTER; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; WART VIRUS;

AGE FACTORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY NEOPLASMS; KIDNEY TRANSPLANTATION; PROGNOSIS; RENAL DIALYSIS; TISSUE DONORS; UREMIA; VIRUS DISEASES;

EID: 21844476787     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphoma in transplant patients. Transplant Proc 1969; 1: 106-112.
2. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. In: Terasaki P, Cecka JM (eds) Clinical Transplants, Los Angeles: UCLA Tissue Typing Laboratory, 1994: 99-109.
3. Birkeland SA, Storm HH, Lamm LU et al. Cancer risk after renal transplantation in the Nordic countries, 1946-1986. Int J Cancer 1995; 60: 1425-1426.
4. Sheil AGR, Disney APS, Mathew TH, Amiss N. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993; 25: 1383-1384.
5. Penn I. Epidemiology of cancer in transplant recipients. In: Touraine JL, Traeger J, Beruel H, et al (eds). Cancer in Transplantation. Prevention and Treatment, London: Kluwer Academic, 1996: 3-15.
6. Penn I. Posttransplant malignancies. Transplant Proc 1999; 31: 1260-1262.
7. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive therapy. Am J Med 1985; 78(Suppl 1A): 44-49.
8. Fairley CK, Sheil AGR, McNeil JJ, et al. The risk of anogenital malignancies in dialysis and transplant patients. Clin Nephrol 1994; 41: 101-105.
9. Shiel AGR, Disney APS, Mathew TH, Amiss N. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993; 25: 1383-1384.
10. Penn I. Malignancy after immunosuppressive therapy: how can the risk be reduced? Clin Immunother 1995; 9: 207-218.
11. Montagnino G, Bencini PL, Trantino A, et al. Clinical features and course of Kaposi's sarcoma in kidney transplant patients: report of 13 cases. Am J Nephrol 1994; 14: 121-126.
12. Vogt P, Frei U, Repp H, et al. Malignant tumors in renal transplant recipients receiving cyclosporine: survey of 598 first kidney transplantations. Nephrol Dial Transplant 1990; 5: 282-288.
13. Kishikawa H, Ichikawa Y, Yazawa K, et al. Malignant neoplasm in kidney transplantation. Int J Urol 1998; 5: 521-525.
14. Ota K, Yamashita N, Agishi T. Malignant tumors in dialysis patients: A nationwide survey. Proc EDTA 1981; 18: 724-730.
15. Ishikawa I. Acquired cystic disease and renal tumors in long-term dialysis patients. In Brown EA, Parfrey PS (eds) Complications of long-term dialysis, Oxford: Oxford University Press, 1999: 145-169.
16. Hojo M, Morimoto T, Malccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534.
17. London NJ, Farmey SM, Will EJ, et al. Risk of neoplasia in renal transplant patients. Lancet 1995; 346: 403-405.
18. Montagnino G, Lorca E, Trantino A, et al. Cancer incidence in 854 kidney transplant recipients from a single institution: comparison with normal population and with patients under dialytic treatment. Clin Transplant 1996; 10: 461-469.
19. Bustami RT, Ojo AO, Wolfe RA, Port FK, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 87-93.
20. zur Hausen. Virus in human cancers. Science 1991; 254: 1167-1173.
21. Bavinck JNB, Berkhout RJM. HPV infection and immunosuppression. Clin Dermatol 1997; 15: 427-437.
22. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestation in children. Transplantation 1988; 45: 719-727.
23. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 1995; 332: 1181-1185.
24. Birkeland SA, Bendzen K, Moller B, et al. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 1999; 67: 876-881.
25. Chetty R, Biddolph S, Kaklamanis L, et al. Bcl-2 proteins strongly expressed in posttransplant lymphoproliferative disorders. J Pathol 1996; 180: 254-258.
26. Fisher DE: Apoptosis and cancer. Cell 1994; 8: 539-542.
27. Nakamura S, Salahuddin SZ, Biberfeld P, et al. Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4 + T-cells. Science 1988; 242: 426-430.
28. Nalesnik MA, Starzl TE. On the crossroad between tolerance and posttransplant lymphoma. Curr Opin Organ Transplant 1997; 2: 30-35.
29. Goldstein DJ, Austin JHM, Zuech N, et al. Carcinoma of the lung after heart transplantation. Transplantation 1996; 62: 772-775.
30. Brunner FP, Landais P, Selwood NH. Malignancies after renal transplantation: The EDTA-ERA registry experience. Nephrol Dial Transplant 1995; 10(Suppl 1): 74-80.
31. Birkeland SA. Malignancies occurring de novo after transplantation. Curr Opin Organ Transplant 1998; 3: 82-89.
32. Moriwaki S, Ray S, Tarone RE, et al. The effect of donor age on the processing of UV-damaged DNA by cultural human cells: reduced DNA repair capacity and increased DNA mutability. Mutat Res 1996; 364: 117-123.
33. Bouwes-Bavinck JN, Vermeer BJ, Van der Woude FJ, et al. Relation between skin cancer and HLA antigens in renal transplant recipients. N Engl J Med 1991; 325: 843-848.
34. Montagnino G, Bencini PL, Trantino A, et al. Clinical features and course of Kaposi's sarcoma in kidney transplant patients: report of 13 cases. Am J Nephrol 1994; 14: 121-126.
35. Parravicini C, Olsen SJ, Capra M, et al. Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients. Blood 1997; 90: 2826-2829.
36. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 1997; 2: 14-17.
37. Iwatsuki S, Gordon G, Shaw BW, Starzl TE. Role of liver transplantation in cancer therapy. Ann Surg 1985; 202: 401-407.
38. Kahan BD, Ponticelli C. Malignancy. In: Kahan BD, Ponticelli C (eds) Principles and practice of renal transplantation. London: Martin Dunitz, 2001: 636.
39. Penn I. Transmission of cancer from organ donors. Ann Transplant 1997; 2: 7-12.
40. Tolkoff-Rubin NE, Rubin RH. Viral infections in organ transplantation. Transplant Proc 1998; 30: 2060-2063.
41. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1984; 323: 583-587.
42. Qunibi W, Akhtar M, Sheth K, et al. Kaposi's sarcoma: the most common tumor after renal transplantation in Saudi Arabia. Am J Med 1988; 84: 225-232.
43. Medveczky MM, Horvath E, Lund T, Medveczky PG. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 1997; 11: 1327-1332.
44. Robles R, Lugo D, Gee L, Jacobson MA. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. AIDS Res Hum Retroviruses 1999; 20: 34-38.